Tradit ionally, otolaryngologists have embraced new technology and applied it quickly to enhance patient care . The operating microscope, superior surgical instrumentation, advanc ed operative laryngoscopes,flexible endoscopes, sinus endoscopes, strobovideolaryngoscopy, and other advances have been embraced for their ability to improve diagnostic accuracy and surgical precis ion. Twenty-first-century technology offers even greater possibilities to achieve meticulously precise diagnosis and intervention, and otolaryngology patients are likely to benefit from our involvement in research using the latest moda lities . Nanomedicine provides new opportunities that have not been explored widely by otolaryngologists .
INDICATION AND IMPORTANT SAFETY INFORMATION
128 mcg for children aged 6 to 12 years. Prescribe the lowest amount necessary for control of symptoms • The overall incidence of adverse events with RHINOCORT AQUA was similar to that observed with vehicle placebo. In clinical trials, commonly rep:>rted adverse events with RHINOCORT AQUA versus vehicle placebo were epistaxis (8% vs 5%). pharyngitis (4% vs 3%1. bronchospasm (2% vs 1%1. coughing (2% vs < 1%1. and nasal irritation (2% vs < 1%) 4107 • RHINOCORT AQUA is indicated for the management of nasal symptoms of seasonal or perennial allergic rhinitis in adults and children 6 years of age and older • Maximum benefit may not be achieved until approximately 2 weeks oher initiation of treatment. Effectiveness depends on regular use
• The recommended starting dosage of RHINOCORT AQUA is 1 spray per nostril once daily (64 mcg total daily dose). with individualized dosing up to 256 mcg for adults and * Overall, the results of the clinical trials showed that RHINOCORT AQUA administered once doily provides statistically significant reduction in the severity of nasal symptoms of seasonal and perennial allergic rhinitis, including runny nose, sneezing, and nasal congestion.
Please see adjacent page for Brief Summary of full Prescribing Information. www 
CONTRAINDICATIONS
Hypersensitivity to any of the ingredients in thi s preparati on contraindicates the use of RHINOCORT AOUA Nasal Spray.
WARNINGS Thereplacement of asystemic corticosteroid wit h atopical corticosteroid can beaccompanied bysignsofadrenal insuf ficiency, andinadditionsome patients mayexperience symptoms ofcorticoste roi dwithdrawal, eg, joint and/or muscular pain, lassitude, and depressio n. Patients previousl y treat ed forprolonged periods with systemic corticosteroids and transf erred to topical corticosteroids should be carefullymonitored for acuteadrenal insufficiency in response to stress. In those patients who have asthma or other clini cal condi tionsrequiring long-term systemic cort icosteroidtreatment, too rapidadecreaseinsystemic corticosteroidsmay cause asevereexacerbation oftheir symptoms. Patients whoareondrugs which suppress theimmune systemare more susceptible to infectionsthan heal thy indi vi duals. Chicken pox and measles, forexample, can have a more serious oreven fatal course in nonimmunechildren oradults onimmunosuppressant dosesof corticosteroi ds. Insuch childrenor adultswho havenot had thesediseases, part icularcareshould betakentoavoidexposure. Howthedose, route, anddurat ion of corticosteroi d administrationaffects therisk of devel oping adisseminat ed infection is not known. Thecontribution ofthe underl ying di seaseand/or priorcort icosteroid treatmentto the risk is alsonot known. If exposed to chicken pox, prophylaxiswithvaricellazoster immunegl obulin(VZI G) may beindicated. If exposed tomeasles, prophylaxiswi th pooled intramuscularimmunoglobuli n (IG) may beindicated. (Seetherespectivepackageinsertsfor completeVZIG and IG prescribinginformation). If chicken poxdevelops, treatmentwithantivi ral agentsmay beconsidered. decrease inmaternal body-I 'leightgain,atsubcutaneousdosesof 20mcglkgand above (less thanthemaximumrecommended daily int ranasal dose in adultsona mcg/m 2 basis). No such effects were noted at5 mcglkg (less than the maxi mum recommended daily intranasal dose in adults on a mcg/m 2 basis) . Pr egnancy: Teratogenic EIIects: Pr egnancy Category B: The impact of budesonide on human pregnancy outcomes hasbeen evaluated through assessments ofbi rth registries linked wit h maternal usage of inhaled budesonide (ie, PULMICORTTURBUHALER) and intranasally administered budesonide (ie, RHINOCORT AQUA Nasal Spray). The results from population-based prospectivecohortepidemiological studies reviewingdatafrom three Swedishregistriescovering approximately 99% of the pregnancies from 1995-2001 (i.e., Swedish Medical Bi rth Registry; Registry of Congenital Malformations; ChildCardiol ogy Registry) indicate no increased risk for overall congenitalmal formations fromtheuseof inhaledor intranasal budesonide during early pregnancy. Congenital mal for mations were studied in 2,014infants born to mothers reporti ng the useof inhaled budesonidefor asthma in earlypregnancy (usually 10-1 2 weeks after thelast menstrual period), the period when most major organ malformations occur,' Therateof overall congenital malformat ions was similar compared tothe general population rate(3.8%vs.3.5%,respectively). Thenumberofinf ant s bornwith orof acial cleftsandcardiac defects was similar totheexpected numberin the general population (4children vs. 3.3and 18 children vs.17-1 B, respectively). In a follow-on study bringing the tot al number ofinfants to 2,534, therateof over all congenital malformations among infants whose mothers wereexposedtoinhaled nudesonideduring earlypregnancy Viasnot differentfromtheratefor all newbornbabies duringthesame period(3.6%).2 A third sfudy from the Swedish Medical BirthRegistry of 2,968pregnancies exposed to inhal ed budesonide, the majority ofwhich werefirsttrimester exposures, reportedgest ational age, birth weight, birthlength, stillbi rths, and multiplebirthssi milarfor exposed infants compared tononexposed infants. 3 Congenital mallormationswerestudied in 2,11 3 infants born to mothers repo rting the useofintranasal budesonide in early pregnancy. The rateof overall congenital malformations Vias si milar compared to thegeneral populat ion rate (4.5%vs. 3.5%, respectively). The adjusted odds ratio(OR) was 1. 06 (95%CI 0.B6-1. 31 ). Thenumberofinfants bornwith orofacial cleftswas similar to theexpected number in the gener al population (3 chi ldren vs. 3,respectivel y). The number ofinfants bornwith cardiac defects exceeded that expected in the general population (2Bchil dren vs. 17.Brespectively). Thesystemic exposure from int ranasal budesonide is 6-fold less than from inhaled budesonide and an association of cardiac defects was not seen with higher exposures of budesonide. As withother corticosteroids, budesonidewas teratogenic and embryocidal in rabbits and rats. Budesonide produced fetal loss, decreased pup weights,and skeletal abnormalities atsubcutaneous dosesof 25mcg/kg inrab bi tsand500mcg/kg inrats(approximately 2and16times themaximum recommendeddaily intranasaldose inadults onamcg/m 2 basis). Inanother study inrat s, noteratogenic or embryocidal effects were seenatinhalationdoses upto 250mcg/kg (approximately Btimesthe maximum recommended dail y intranasal dose in adultson a mcg/m 2 basis). Experiencewith oral cort icosteroids since their intr oduct ion inpharmacologic, as opposedtophysiologicdosessuggests that rodentsaremorepronetoteratogenic effects from corticosteroi dsthan humans. In addition, because there is an increase in corticosteroid production during pregnancy, mostwomen will requirealower exogenouscorticosteroid doseandmany will not need corticosteroid treatmentduring pregnancy. Despitetheanimal findings, it wouldappear that the possibilityof fetal harmis remoteif thedrug isusedduringpregnancy. Nevertheless, becausethestudies inhumanscannot ruleout thepossibilityof harm, RHINOCORT AQUAshouldbeused during pregnancy only if clearly needed. Nonleratogenic Eff ects: Hypoadrenalism may occur in infants born of mothers receivi ng corticosteroi ds during pregnancy . Such inf ants should becarefullyobserved. Nursing Mathers: It is not known whether budesonide is excreted In human milk. Because other corticosteroids are excreted in human milk, caution should be exercised when RHINOCORT AQUA Nasal Spray isadministered tonur singwomen. Pediatric Use: Safety andeffectiveness inpediatricpatientsbel ow6 yearsof age havenot been established. Controlled clinical studies have shown thatintranasal corticosteroidsmay causeareductioningrowth velocity inpediat ricpatients,Thiseffect has beenobser ved intheabsence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA)-axissuppression, suggesting that growth velocityisamoresensitiveindicatorof systemic corticosteroid exposure in pediatricpatients than some commonlyusedtests ofHPA-axis function. The long-term effects of this reduction in growth veloc ity associated wi th intranasal corticosteroi ds, includingtheimpact onfinal adult height,areunknown.Thepotential for "catchup"grol'rthfollowingdiscontinuation of treatment with intranasal corticosteroids has not been adequately studied. The grol'rth of pediatric patients receiving intranasal corticosteroids, including RHINOCORT AOUA Nasal Spray , shoul dbe monitoredroutinely(eg,via stadiometry). The potential growth effects of prol onged treatment should be weighed against cli nical benefits obtained andtheavailability of safeandeffective noncorticosteroidtreatmentallernatives. To minimize the systemic effectsof intranasalcort icosteroids, includi ng RHINOCORTAQUA NasalSpray, eachpatient shoul d betitratedtothe lowest dose that eff ectively controls his/her symptoms. A one-yearplacebo-controlled clinical grol' rth studywas conducted in229 pediatricpatients(ages 4through Byearsofage)toassess theeffect of RHINOCORT AQ UA (si ngledailydose of 64mcg, therecommended startingdoseforchildrenages 6years andabove) ongrowth velocity. From apopulationof 141 patientsreceiving RHINOCORTAQUA Nasal Spray and67 receiving placebo, the pointestimate for grol'rthvelocity wi thRHINOCORTAQUANasal Spray Vias 0.25cm/year lowerthanthat noted with placebo(95% confidence interval rangingfrom0.59cmlyear lower thanpl acebotoO .O Bcm/ year higher than placebo). Thepotential forRHINOCORTAQUAtocause grol'rthsuppression insusceptiblepat ientsorwhengi ven atdoses above 64mcg dailycannot beruledout.Therecommendeddosagerangeinpatients6to11yearsof ageis64to128mcgperday (seeDOSAGEANDADMINISTRATION) . GeriatricUse:Of the2,461 pat ientsincli nical studies of RHINOCORT AQUA Nasal Spray, 5% were60 years of age and over . No overall differ ences in safety or effectiveness wereobserved between these SUbjects and younger subjects, except for an adverse event reporting frequency of epistaxis which increased wit hage. Further, other reported clinical experience has notidentifiedanyotherdifferencesinresponses bet ween el derlyandyounger pat ients, butgreater sensi tivityof some older individualscannot be ruledout.
ADVERSE REACTIONS
The incidence of common adverse reactions is based upon two U.S. and five non-U.S. controlled clinical trial s in 1,526patients[110 females and 239 males lessthan 18yearsofage,and 635 females and542malesl Byearsofage and older] treatedwi th RHINOCORTAQ UA Nasal Spray at dosesupto400 mcg once dailyfor 3-6 weeks. Thetable belowdescribes adverse eventsoccurring atanincidenceof 2%or greater and morecommon among RHINOCORT AQUA Nasal Spray-treated patientsthaninplacebo-treatedpatients incontrolled cli nical trials. Theoverall incidence ofadverse events Vias simil ar bet ween RHINOCORTAQ UA andplacebo. 
